Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Adavosertib + Carboplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Adavosertib||MK-1775|AZD1775|AZ1775||WEE1 Inhibitor 4||Adavosertib (MK-1775) is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity (PMID: 22084170).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Adavosertib + Carboplatin||Phase Ib/II||Actionable||In a Phase Ib trial, Adavosertib (MK-1775) in combination with Paraplatin (carboplatin) was tolerable and resulted in partial response in 16.7% (1/3) of patients and stable disease in 33.3% (2/6) of Asian patients with advanced solid tumors (PMID: 32034630).||32034630|
|Unknown unknown||Advanced Solid Tumor||not applicable||Adavosertib + Carboplatin||Phase I||Actionable||In a Phase I trial, the combination of Adavosertib (MK-1775) and Paraplatin (carboplatin) resulted in a partial response in 6.5% (4/62) of patients and stable disease in 45% (28/62) of patients, all with advanced solid tumors (PMID: 27601554).||27601554|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02272790||Phase II||Adavosertib + Carboplatin Adavosertib + Gemcitabine Adavosertib + Paclitaxel||A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.||Active, not recruiting|
|NCT01827384||Phase II||Adavosertib + Carboplatin Temozolomide + Veliparib Everolimus Trametinib||Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors||Recruiting|